


Product Data Sheet

RMC-6236

Cat. No.:	A9992
CAS No.:	2765081-21-6
Formula:	C ₄₄ H ₅₈ N ₈ O ₅ S
M.Wt:	811.06
Synonyms:	Daraxonrasib
Target:	KRas G12D
Pathway:	MAPK/ERK Pathway
Storage:	Store at -20°C for 3 years.



Solvent & Solubility

Soluble in DMSO

In Vitro

	Solvent	Mass	1mg	5mg	10mg
Preparing					
Stock Solutions	Concentration				
	1 mM		1.233	6.1648	12.3295
	5 mM		0.2466	1.233	2.4659
	10 mM		0.1233	0.6165	1.233

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Rsc-6236 (Compound A122) is a novel and highly effective inhibitor of RAS(ON) MULTI. RAS proteins are frequently mutated and continuously activated in a variety of cancers, driving the proliferation and survival of tumor cells. RMC-6236 effectively blocks downstream signaling pathways by specifically binding to and inhibiting the active form of RAS protein (RAS(ON)), thereby inhibiting the growth and spread of cancer cells. Studies have shown that RCAC-6236 exhibits significant antitumor activity in a variety of cancer models, particularly for cancer types carrying RAS mutations, such as lung, pancreatic, and colorectal cancers.

 IC₅₀ & Target

1.2 nM for HPAC cells

In Vitro	Cell Viability Assay	
	Cell Line:	NCI-H441, Capan-2, HPAC, isogenic RAS-less MEF cells
	Preparation method:	RMC-6236 was resuspended in dimethyl sulfoxide (DMSO) and used at 10 mmol/L stock concentration. Cells were exposed to serial dilutions of compound or DMSO control (0.1% v/v) for specified time points using a Labcyte Echo 550 or Tecan D300e digital dispenser. Following incubation, cells were lysed, and the levels of ERK phosphorylation were determined using AlphaLISA.
	Reacting conditions:	4-48h, 1-30 nM.
	Applications:	RMC-6236 (EC50 of 1.2 nM for HPAC cells and 1.4 nM for Capan-2 cells; 120 h) potentially inhibits the growth of KRAS mutant cancer cell lines HPAC and Capan-2
In Vivo	Animal experiment	
	Animal models:	Nude mice
	Dosage form:	20 mg/kg po qd, 3 weeks
	Applications:	Daily treatment with RMC-6236 drove significant and consistent reductions in tumor burden across all oncogenic Kras variants tested.
	Preparation method:	RMC-6236 was prepared using formulation of 10/20/10/60 (%v/v/v/v) DMSO/PEG 400/Solutol HS15/water. Tumors were initiated via intratracheal delivery of lentivirus to the lungs of mice. 13 weeks post tumor initiation, mice were treated for 3 weeks with either: (i) vehicle (10% DMSO, 20% PEG400, 10% Solutol HS15, 60% water) po qd and 10 mg/kg isotype rat igg2a[2a3] ip biw; or (ii) RMC-6236 20 mg/kg po qd.
	Other notes:	The technical data provided above is for reference only.

Product Citations

/

See more customer validations on www.apexbt.com.

References

1. Jiang J, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discov. 2024 Jun 3;14(6):994-1017.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

